NeoGenomics NEO Reportable Segment — Total stock-based compensation
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by NeoGenomics in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about NeoGenomics's reportable segment — total stock-based compensation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NeoGenomics's reportable segment — total stock-based compensation?
- NeoGenomics (NEO) reported reportable segment — total stock-based compensation of $9.64M in Q1 2026.
- How has NeoGenomics's reportable segment — total stock-based compensation changed year-over-year?
- NeoGenomics's reportable segment — total stock-based compensation decreased by 10.4% year-over-year, from $10.75M to $9.64M.
- What is the long-term trend for NeoGenomics's reportable segment — total stock-based compensation?
- Over 3 years (2022 to 2025), NeoGenomics's reportable segment — total stock-based compensation has grown at a 18.8% compound annual growth rate (CAGR), from $24.67M to $41.32M.
- What does reportable segment — total stock-based compensation mean?
- The total expense recognized for equity-based awards granted to employees and management within the segment. This metric is critical for evaluating the true cost of human capital and the potential dilution impact on existing shareholders.